Antibody fragments have become essential tools in modern therapeutic research, offering smaller size, higher tissue penetration, and improved stability compared to full-length antibodies. At Yaohai Bio-Pharma, we focus on leveraging advanced microbial expression systems to produce nanobody and antibody fragment molecules efficiently and at high yield. Our platforms integrate both E.coli and yeast systems, which allow us to tailor expression strategies to different protein types and project scales. By combining cutting-edge fermentation and downstream purification processes, we ensure that every antibody fragment meets rigorous functional and quality standards, enabling researchers to accelerate preclinical and clinical studies.
Optimized Microbial Expression Platforms
We have developed optimized microbial platforms that maximize protein production while preserving molecular structure and biological activity. Our high-density fermentation processes, combined with precision downstream purification, enable consistent production of high-quality nanobody constructs. These systems provide flexibility for various project scales, from small laboratory batches to clinical-grade production. With experience in over a hundred projects, including IND-supported studies and clinical-grade protein supply, Yaohai Bio-Pharma can reliably produce antibody fragment molecules with reproducible yields and purity. Our approach ensures a seamless transition from discovery research to larger-scale manufacturing without compromising product integrity.
Comprehensive CDMO Services and Quality Assurance
At Yaohai Bio-Pharma, we provide full-process CDMO services, covering gene optimization, strain development, small- and large-scale expression, purification, and formulation. Our production capacity ranges from 50L to 2000L, supported by multiple GMP-compliant microbial fermentation and purification lines. Every step of our antibody fragment and nanobody production undergoes rigorous quality control using modern analytical techniques, including SDS-PAGE and HPLC. This robust quality framework ensures reproducibility, supports regulatory submissions, and accelerates timelines from early research to clinical application. The Nanobody products we provide exemplify how our microbial expertise translates into reliable, scalable therapeutics ready for research or clinical use.
Conclusion: Advancing Therapeutic Antibody Fragments
In conclusion, Yaohai Bio-Pharma’s microbial systems provide a highly efficient, scalable platform for nanobody and antibody fragment manufacturing. By integrating advanced microbial expression technologies with rigorous quality control and full-process CDMO services, we support biotech companies in accelerating development while reducing risk. Our flexible production scales, combined with GMP compliance and technical expertise, ensure that every antibody fragment is of high purity, functional, and suitable for preclinical or clinical applications. Choosing Yaohai Bio-Pharma allows our clients to leverage proven microbial systems for faster project timelines, consistent production, and reliable access to high-quality biologics, highlighting the critical role of microbial CDMO platforms in modern biopharmaceutical innovation.
